In HIV-seropositive patients on antiretroviral therapy (ART) with non-infectious diarrhea, crofelemer 125mg twice daily was well tolerated with a low incidence of adverse events and no clinical deterioration of immune status, study investigators reported at IDWeek 2013.
Hepatitis B virus (HBV) vaccine response status was not associated with post-combination antiretroviral therapy (cART) CD4 gains at 1-year among those with virologic suppression, a study concluded at IDWeek 2013.
A single dose of benzathine penicillin G is sufficient to treat patients with HIV infection and early syphilis, a study presented at IDWeek 2013 has found.
Treatment with sofosbuvir + peginterferon alfa-2a/ribavirin for 12 weeks in treatment-naïve, HIV/HCV co-infected patients led to a highly effective sustained virologic response rate, results of a study presented at IDWeek 2013.
Week 48 “snapshot analysis” finds two single tablet regimens non-inferior for virologic suppression in treatment-naïve patients with HIV-1 infection, the STaR study reported at IDWeek 2013.
Patients with HIV-1 treated with rilpivirine/emtricitabine/tenofovir DF once-daily single-tablet regimen maintained virologic suppression at 48 weeks regardless of initiation time.
Elvitegravir/cobicistat/emtricitabine/tenofovir DF was well-tolerated and safe compared with efavirenz/emtricitabine/tenofovir DF in treatment-naïve Black patients with HIV infection, a study presented at IDWeek 2013 has found.
Single-dose azithromycin has comparable efficacy to benzathine penicillin G for the treatment of early syphilis among HIV-positive patients, in areas with a low prevalence of macrolide-resistant Treponema pallidum, according to results discussed at IDWeek 2013.
Elderly females may have a better immune response to the 23-valent pneumococcal polysaccharide vaccine (PPV23) than males for the prevention of S. pneumoniae community-acquired pneumonia. (IDWeek 2013)
Single tablet fixed-dose antiretroviral combination regimens, may improve virologic outcomes among urban populations of HIV-infected persons compared with multiple tablet regimens, as presented at IDWeek 2013.
Please login or register first to view this content.
